The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2014

Filed:

Dec. 19, 2008
Applicants:

Peter Birk Rasmussen, Horsholm, DK;

Martin Roland Jensen, Horsholm, DK;

Klaus Gregorius Nielsen, Horsholm, DK;

Peter Koefoed, Horsholm, DK;

Florence Dal Degan, Horsholm, DK;

Inventors:

Peter Birk Rasmussen, Horsholm, DK;

Martin Roland Jensen, Horsholm, DK;

Klaus Gregorius Nielsen, Horsholm, DK;

Peter Koefoed, Horsholm, DK;

Florence Dal Degan, Horsholm, DK;

Assignee:

H. Lundbeck A/S, Valby, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/385 (2006.01); A61K 39/08 (2006.01); A01K 67/027 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0007 (2013.01); A61K 39/385 (2013.01); A01K 67/0275 (2013.01); C07K 14/4711 (2013.01); A61K 2039/53 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/6087 (2013.01); A61K 2039/6093 (2013.01); A61K 2039/64 (2013.01); A01K 2217/05 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0312 (2013.01);
Abstract

Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogs of autologous APP or Aβ, said analogs being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.


Find Patent Forward Citations

Loading…